Data validates multimodal AI biomarker’s ability to help inform treatment decisions omCSPC

UCLA Urology awarded $6M from CA Department of Health Care Services to serve vulnerable patients with prostate cancer

UCLA’s urology department was awarded $6 million from the California Department of Health Care Services to continue providing care and critical services to underinsured and uninsured Californians diagnosed with prostate cancer.

October 25, 2024

Vol.50 No.40

In Brief

UCLA’s Luca Valle receives $2.1M grant from VA to improve prediction of radiorecurrent prostate cancer outcomes

Luca Valle, assistant professor of radiation oncology at the David Geffen School of Medicine at UCLA, was awarded a $2.1 million grant from the U.S. Department of Veterans Affairs to develop new methods to better understand the clinical scope and biological factors that lead to prostate cancer coming back after radiation therapy.

October 25, 2024

Vol.50 No.40

In Brief

OmniaBio opens commercial manufacturing facility in Canada, bringing cell and gene therapies to patients

OmniaBio Inc. announced the opening of a new North American cell and gene therapy manufacturing and artificial intelligence center of excellence, which is now Canada’s largest contract development and manufacturing organization facility dedicated to CGT.

October 25, 2024

Vol.50 No.40

Clinical Roundup

East Alabama Medical Center, Inflo Health, ACR ImPower program collaboration boosts recommendations follow-up by 74%

Inflo Health, a leader in AI-driven radiology follow-up care orchestration, announced that it has qualified for the American College of Radiology’s Learning Network Vendor Partner designation on the heels of a successful collaboration that saw East Alabama Medical Center significantly improve recommendations follow-up rates.

October 25, 2024

Vol.50 No.40

In Brief

David Baker, Demis Hassabis, and John Jumper receive 2024 Nobel Prize in Chemistry

David BakerPhoto credit: Niklas Elmehed © Nobel Prize OutreachDemis HassabisPhoto credit: Niklas Elmehed © Nobel Prize OutreachJohn M. JumperPhoto credit: Niklas Elmehed © Nobel Prize OutreachDavid Baker, Demis Hassabis, and John M. Jumper received the 2024 Nobel Prize in Chemistry for their work in protein design and prediction.

October 11, 2024

Vol.50 No.38

Clinical Roundup

Study shows an early blood test can predict survival in metastatic prostate cancer patients

A blood test, performed when metastatic prostate cancer is first diagnosed, can predict which patients are likely to respond to treatment and survive the longest.

October 11, 2024

Vol.50 No.38

Data validates multimodal AI biomarker’s ability to help inform treatment decisions omCSPC

YOU MAY BE INTERESTED IN

UCLA Urology awarded $6M from CA Department of Health Care Services to serve vulnerable patients with prostate cancer

UCLA’s Luca Valle receives $2.1M grant from VA to improve prediction of radiorecurrent prostate cancer outcomes

OmniaBio opens commercial manufacturing facility in Canada, bringing cell and gene therapies to patients

East Alabama Medical Center, Inflo Health, ACR ImPower program collaboration boosts recommendations follow-up by 74%

David Baker, Demis Hassabis, and John Jumper receive 2024 Nobel Prize in Chemistry

Study shows an early blood test can predict survival in metastatic prostate cancer patients

Renew today!

Subscriber content

Login